Ratifi English Iniciar sesión
Ratifi

Proyectos federales de Congress.gov. Proyectos estatales de Open States.

SB 1768Sesión 2025

Qué cambió entre versiones

8 párrafos cambiaron+7 palabras agregadas−9 eliminadas

El texto resaltado se agregó en la versión más reciente. El texto tachado se eliminó.

ENROLLED

2025

Legislature

CS for CS for SB 1768, 1st Engrossed

First Engrossed

20251768e120251768er

1 A bill to be entitled

1

2 An act relating to stem cell therapy; creating ss.

709 párrafos sin cambios

3 458.3245 and 459.0127, F.S.; providing legislative

4 findings and intent; defining terms; authorizing

5 physicians to perform stem cell therapy not approved

6 by the United States Food and Drug Administration

7 under certain circumstances; specifying requirements

8 for the stem cells that may be used by such

9 physicians; requiring such physicians to adhere to

10 applicable current good manufacturing practices in the

11 performance of such therapies; requiring physicians to

12 include a specified notice in any form of

13 advertisement; providing requirements for such notice;

14 requiring physicians to obtain a signed consent form

15 from the patient or his or her representative before

16 performing the therapy; specifying requirements for

17 the consent form; providing applicability; providing

18 for disciplinary action; providing criminal penalties;

19 authorizing the Board of Medicine to adopt rules;

20 providing an effective date.

21

22 Be It Enacted by the Legislature of the State of Florida:

23

24 Section 1. Section 458.3245, Florida Statutes, is created

25 to read:

26

458.3245 Stem cell therapy.—

27

(1) The Legislature recognizes the significant potential of

28

stem cell therapies in advancing medical treatments and

29

improving patient outcomes and further recognizes the need to

30

ensure that such therapies are provided using stem cells

31

obtained in an ethical manner that does not involve stem cells

32

derived from aborted fetuses. It is the intent of the

33

Legislature to foster medical innovation while upholding ethical

34

standards that respect the sanctity of life. By encouraging the

35

use of stem cell sources such as adult stem cells, umbilical

36

cord blood, and other ethically obtained human cells, tissues,

37

or cellular or tissue-based products, the state will advance

38

regenerative medicine in a manner consistent with the values of

39

this state.

40

(2) As used in this section, the term:

41

(a) “Human cells, tissues, or cellular or tissue-based

42

products” means articles containing or consisting of human cells

43

or tissues that are intended for implantation, transplantation,

44

infusion, or transfer into a human recipient. The term does not

45

include:

46

1. Vascularized human organs for transplantation;

47

2. Whole blood or blood components or blood derivative

48

products;

49

3. Secreted or extracted human products, such as milk,

50

collagen, and cell factors, other than semen;

51

4. Minimally manipulated bone marrow for homologous use and

52

not combined with another article other than water,

53

crystalloids, or a sterilizing, preserving, or storage agent, if

54

the addition of the agent does not raise new clinical safety

55

concerns with respect to the bone marrow;

56

5. Ancillary products used in the manufacture of human

57

cells, tissues, or cellular or tissue-based products;

58

6. Cells, tissues, and organs derived from animals other

59

than humans;

60

7. In vitro diagnostic products; or

61

8. Blood vessels recovered with an organ which are intended

62

for use in organ transplantation and labeled “For use in organ

63

transplantation only.”

64

(b) “Minimally manipulated” means:

65

1. For structural tissue, processing that does not alter

66

the original relevant characteristics of the tissue relating to

67

the tissue’s utility for reconstruction, repair, or replacement.

68

2. For cells or nonstructural tissues, processing that does

69

not alter the relevant biological characteristics of cells or

70

tissues.

71

(c) “Physician” means a physician licensed under this

72

chapter acting in the course and scope of his or her employment.

73

(d) “Stem cell therapy” means a treatment involving the use

74

of afterbirth placental perinatal stem cells, or human cells,

75

tissues, or cellular or tissue-based products, which complies

76

with the regulatory requirements provided in this section. The

77

term does not include treatment or research using human cells or

78

tissues that were derived from a fetus or an embryo after an

79

abortion.

80

(3)(a) A physician may perform stem cell therapy that is

81

not approved by the United States Food and Drug Administration

82

if such therapy is used for treatment or procedures that are

83

within the scope of practice for such physician and the

84

therapies are related to orthopedics, wound care, or pain

85

management.

86

(b) To ensure that the retrieval, manufacture, storage, and

87

use of stem cells used for therapies conducted under this

88

section meet the highest standards, any stem cells used by a

89

physician for therapy provided under this section must:

90

1. Be retrieved, manufactured, and stored in a facility

91

that is registered and regulated by the United States Food and

92

Drug Administration;

93

2. Be retrieved, manufactured, and stored in a facility

94

that is certified or accredited by one of the following

95

entities:

96

a. National Marrow Donor Program.

97

b. World Marrow Donor Association.

98

c. Association for the Advancement of Blood and

99

Biotherapies.

100

d. American Association of Tissue Banks; and

101

3. Contain viable or live cells upon post-thaw analysis and

102

be included in a post-thaw viability analysis report for the

103

product lot which will be sent to the physician before use with

104

the physician’s patient.

105

(c) A physician performing stem cell therapy may not obtain

106

stem cells for therapies from a facility engaging in the

107

retrieval, manufacture, or storage of stem cells intended for

108

human use under this section unless the facility maintains valid

109

certification or accreditation as required by this subsection.

110

Any contract or other agreement by which a physician obtains

111

stem cells for therapies from such a facility must include the

112

following:

113

1. A requirement that the facility provide all of the

114

following information to the physician:

115

a. The name and address of the facility.

116

b. The certifying or accrediting organization.

117

c. The type and scope of certification or accreditation.

118

d. The effective and expiration dates of the certification

119

or accreditation.

120

e. Any limitations or conditions imposed by the certifying

121

or accrediting organization.

122

2. A requirement that the facility notify the physician

123

within 30 days after any change in certification or

124

accreditation status, including renewal, suspension, revocation,

125

or expiration.

126

(4) In the performance of any procedure using or purporting

127

to use stem cells or products containing stem cells, the

128

physician shall use stem cell therapy products obtained from

129

facilities that adhere to the applicable current good

130

manufacturing practices for the collection, removal, processing,

131

implantation, and transfer of stem cells, or products containing

132

stem cells, pursuant to the Federal Food, Drug, and Cosmetic

133

Act, 21 U.S.C. ss. 301 et seq.; 52 Stat. 1040 et seq.; and 21

134

C.F.R. part 1271, Human Cells, Tissues, and Cellular and Tissue

135

Based Products.

136

(5)(a) A physician who conducts stem cell therapy pursuant

137

to this section shall include the following in any form of

138

advertisement:

139

140

THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.

141

This physician performs one or more stem cell

142

therapies that have not yet been approved by the

143

United States Food and Drug Administration. You are

144

encouraged to consult with your primary care provider

145

before undergoing any stem cell therapy.

146

147

(b) The notice required under paragraph (a) must be clearly

148

legible and in a type size no smaller than the largest type size

149

used in the advertisement.

150

(6)(a) A physician who conducts stem cell therapy pursuant

151

to this section shall obtain a signed consent form from the

152

patient before performing the stem cell therapy.

153

(b) The consent form must be signed by the patient or, if

154

the patient is not legally competent, the patient’s

155

representative and must state all of the following in language

156

the patient or his or her representative may reasonably be

157

expected to understand:

158

1. The nature and character of the proposed treatment.

159

2. That the proposed stem cell therapy has not yet been

160

approved by the United States Food and Drug Administration.

161

3. The anticipated results of the proposed treatment.

162

4. The recognized serious possible risks, complications,

163

and anticipated benefits involved in the treatment and in the

164

recognized possible alternative forms of treatment, including

165

nontreatment.

166

5. That the patient is encouraged to consult with his or

167

her primary care provider before undergoing any stem cell

168

therapy.

169

(7) This section does not apply to the following:

170

(a) A physician who has obtained approval for an

171

investigational new drug or device from the United States Food

172

and Drug Administration for the use of human cells, tissues, or

173

cellular or tissue-based products; or

174

(b) A physician who performs stem cell therapy under an

175

employment or other contract on behalf of an institution

176

certified or accredited by any of the following:

177

1. The Foundation for the Accreditation of Cellular

178

Therapy.

179

2. The Blood and Marrow Transplant Clinical Trials Network.

180

3. The Association for the Advancement of Blood and

181

Biotherapies.

182

4. An entity with expertise in stem cell therapy as

183

determined by the department.

184

(8) A violation of this section may subject the physician

185

to disciplinary action by the board.

186

(9) A physician who willfully performs, or actively

187

participates in, the following commits a felony of the third

188

degree, punishable as provided in s. 775.082, s. 775.083, or s.

189

775.084, and is subject to disciplinary action under this

190

chapter and s. 456.072:

191

(a) Treatment or research using human cells or tissues

192

derived from a fetus or an embryo after an abortion; or

193

(b) The sale, manufacture, or distribution of computer

194

products created using human cells, tissues, or cellular or

195

tissue-based products.

196

(10) The board may adopt rules necessary to implement this

197

section.

198 Section 2. Section 459.0127, Florida Statutes, is created

199 to read:

200

459.0127 Stem cell therapy.—

201

(1) The Legislature recognizes the significant potential of

202

stem cell therapies in advancing medical treatments and

203

improving patient outcomes and further recognizes the need to

204

ensure that such therapies are provided using stem cells

205

obtained in an ethical manner that does not involve stem cells

206

derived from aborted fetuses. It is the intent of the

207

Legislature to foster medical innovation while upholding ethical

208

standards that respect the sanctity of life. By encouraging the

209

use of stem cell sources such as adult stem cells, umbilical

210

cord blood, and other ethically obtained human cells, tissues,

211

or cellular or tissue-based products, the state will advance

212

regenerative medicine in a manner consistent with the values of

213

this state.

214

(2) As used in this section, the term:

215

(a) “Human cells, tissues, or cellular or tissue-based

216

products” means articles containing or consisting of human cells

217

or tissues that are intended for implantation, transplantation,

218

infusion, or transfer into a human recipient. The term does not

219

include:

220

1. Vascularized human organs for transplantation;

221

2. Whole blood or blood components or blood derivative

222

products;

223

3. Secreted or extracted human products, such as milk,

224

collagen, and cell factors, other than semen;

225

4. Minimally manipulated bone marrow for homologous use and

226

not combined with another article other than water,

227

crystalloids, or a sterilizing, preserving, or storage agent, if

228

the addition of the agent does not raise new clinical safety

229

concerns with respect to the bone marrow;

230

5. Ancillary products used in the manufacture of human

231

cells, tissues, or cellular or tissue-based products;

232

6. Cells, tissues, and organs derived from animals other

233

than humans;

234

7. In vitro diagnostic products; or

235

8. Blood vessels recovered with an organ which are intended

236

for use in organ transplantation and labeled “For use in organ

237

transplantation only.”

238

(b) “Minimally manipulated” means:

239

1. For structural tissue, processing that does not alter

240

the original relevant characteristics of the tissue relating to

241

the tissue’s utility for reconstruction, repair, or replacement.

242

2. For cells or nonstructural tissues, processing that does

243

not alter the relevant biological characteristics of cells or

244

tissues.

245

(c) “Physician” means a physician licensed under this

246

chapter acting in the course and scope of his or her employment.

247

(d) “Stem cell therapy” means a treatment involving the use

248

of afterbirth placental perinatal stem cells, or human cells,

249

tissues, or cellular or tissue-based products, which complies

250

with the regulatory requirements provided in this section. The

251

term does not include treatment or research using human cells or

252

tissues that were derived from a fetus or an embryo after an

253

abortion.

254

(3)(a) A physician may perform stem cell therapy that is

255

not approved by the United States Food and Drug Administration

256

if such therapy is used for treatment or procedures that are

257

within the scope of practice for such physician and the

258

therapies are related to orthopedics, wound care, or pain

259

management.

260

(b) To ensure that the retrieval, manufacture, storage, and

261

use of stem cells used for therapies conducted under this

262

section meet the highest standards, any stem cells used by a

263

physician for therapy provided under this section must:

264

1. Be retrieved, manufactured, and stored in a facility

265

that is registered and regulated by the United States Food and

266

Drug Administration;

267

2. Be retrieved, manufactured, and stored in a facility

268

that is certified or accredited by one of the following

269

entities:

270

a. National Marrow Donor Program.

271

b. World Marrow Donor Association.

272

c. Association for the Advancement of Blood and

273

Biotherapies.

274

d. American Association of Tissue Banks; and

275

3. Contain viable or live cells upon post-thaw analysis and

276

be included in a post-thaw viability analysis report for the

277

product lot which will be sent to the physician before use with

278

the physician’s patient.

279

(c) A physician performing stem cell therapy may not obtain

280

stem cells for therapies from a facility engaging in the

281

retrieval, manufacture, or storage of stem cells intended for

282

human use under this section unless the facility maintains valid

283

certification or accreditation as required by this subsection.

284

Any contract or other agreement by which a physician obtains

285

stem cells for therapies from such a facility must include the

286

following:

287

1. A requirement that the facility provide all of the

288

following information to the physician:

289

a. The name and address of the facility.

290

b. The certifying or accrediting organization.

291

c. The type and scope of certification or accreditation.

292

d. The effective and expiration dates of the certification

293

or accreditation.

294

e. Any limitations or conditions imposed by the certifying

295

or accrediting organization.

296

2. A requirement that the facility notify the physician

297

within 30 days after any change in certification or

298

accreditation status, including renewal, suspension, revocation,

299

or expiration.

300

(4) In the performance of any procedure using or purporting

301

to use stem cells or products containing stem cells, the

302

physician shall use stem cell therapy products obtained from

303

facilities that adhere to the applicable current good

304

manufacturing practices for the collection, removal, processing,

305

implantation, and transfer of stem cells, or products containing

306

stem cells, pursuant to the Federal Food, Drug, and Cosmetic

307

Act, 21 U.S.C. ss. 301 et seq.; 52 Stat. 1040 et seq.; and 21

308

C.F.R. part 1271, Human Cells, Tissues, and Cellular and Tissue

309

Based Products.

310

(5)(a) A physician who conducts stem cell therapy pursuant

311

to this section shall include the following in any form of

312

advertisement:

313

314

THIS NOTICE MUST BE PROVIDED TO YOU UNDER FLORIDA LAW.

315

This physician performs one or more stem cell

316

therapies that have not yet been approved by the

317

United States Food and Drug Administration. You are

318

encouraged to consult with your primary care provider

319

before undergoing any stem cell therapy.

320

321

(b) The notice required under paragraph (a) must be clearly

322

legible and in a type size no smaller than the largest type size

323

used in the advertisement.

324

(6)(a) A physician who conducts stem cell therapy pursuant

325

to this section shall obtain a signed consent form from the

326

patient before performing the stem cell therapy.

327

(b) The consent form must be signed by the patient or, if

328

the patient is not legally competent, the patient’s

329

representative and must state all of the following in language

330

the patient or his or her representative may reasonably be

331

expected to understand:

332

1. The nature and character of the proposed treatment.

333

2. That the proposed stem cell therapy has not yet been

334

approved by the United States Food and Drug Administration.

335

3. The anticipated results of the proposed treatment.

336

4. The recognized serious possible risks, complications,

337

and anticipated benefits involved in the treatment and in the

338

recognized possible alternative forms of treatment, including

339

nontreatment.

340

5. That the patient is encouraged to consult with his or

341

her primary care provider before undergoing any stem cell

342

therapy.

343

(7) This section does not apply to the following:

344

(a) A physician who has obtained approval for an

345

investigational new drug or device from the United States Food

346

and Drug Administration for the use of human cells, tissues, or

347

cellular or tissue-based products; or

348

(b) A physician who performs stem cell therapy under an

349

employment or other contract on behalf of an institution

350

certified or accredited by any of the following:

351

1. The Foundation for the Accreditation of Cellular

352

Therapy.

353

2. The Blood and Marrow Transplant Clinical Trials Network.

354

3. The Association for the Advancement of Blood and

355

Biotherapies.

356

4. An entity with expertise in stem cell therapy as

357

determined by the department.

358

(8) A violation of this section may subject the physician

359

to disciplinary action by the board.

360

(9) A physician who willfully performs, or actively

361

participates in, the following commits a felony of the third

362

degree, punishable as provided in s. 775.082, s. 775.083, or s.

363

775.084, and is subject to disciplinary action under this

364

chapter and s. 456.072:

365

(a) Treatment or research using human cells or tissues

366

derived from a fetus or an embryo after an abortion; or

367

(b) The sale, manufacture, or distribution of computer

368

products created using human cells, tissues, or cellular or

369

tissue-based products.

370

(10) The board may adopt rules necessary to implement this

371

section.

372 Section 3. This act shall take effect July 1, 2025.

Volver al texto completo